Home Cardiovascular Disease HAYA Is Developing Therapeutics Targeting Long Non-Coding RNAs

Ribonucleic acid strands [iStock / Getty Images Plus]

HAYA Is Developing Therapeutics Targeting Long Non-Coding RNAs

The Swiss company targets long non-coding RNAs (lncRNAs) for tissue-specific treatment of fibrotic diseases and other medical conditions.

By Jonathan D Grinstein, PhD

June 29, 2022

Ribonucleic acid strands [iStock / Getty Images Plus]

HAYA Therapeutics is a Swiss precision therapeutics company that has developed tools and methods to interrogate lncRNA biology to design tissue- and cell-type-specific genomic medicines. GEN Edge talked to Samir Ounzain, PhD, co-founder and CEO of HAYA Therapeutics, at BIO 2022 in San Diego to catch up on how the company is carving the path to commercializing lncRNA-targeting medicines . . .